| Title |
Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors
|
|---|---|
| Published in |
Molecular Diagnosis & Therapy, January 2013
|
| DOI | 10.1007/s40291-013-0018-7 |
| Pubmed ID | |
| Authors |
Piotr Rutkowski, Joanna Przybył, Marcin Zdzienicki |
| Abstract |
On the basis of the recently published results of a clinical trial comparing 12 and 36 months of imatinib in adjuvant therapy for gastrointestinal stromal tumors (GISTs), which demonstrated clinical benefit of longer imatinib treatment in terms of delaying recurrences and improving overall survival, both the US Food and Drug Administration and the European Medicines Agency have updated their recommendations and approved 36 months of imatinib treatment in patients with v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT)-positive GISTs (also known as CD117-positive GISTs) at high risk of recurrence after surgical resection of a primary tumor. This article discusses patient selection criteria for extended adjuvant therapy with imatinib, different classifications of risk of recurrence, and assessment of the response to therapy. |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Luxembourg | 1 | 5% |
| Unknown | 18 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 21% |
| Student > Doctoral Student | 3 | 16% |
| Student > Bachelor | 3 | 16% |
| Student > Ph. D. Student | 2 | 11% |
| Professor | 1 | 5% |
| Other | 2 | 11% |
| Unknown | 4 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 42% |
| Agricultural and Biological Sciences | 2 | 11% |
| Biochemistry, Genetics and Molecular Biology | 1 | 5% |
| Business, Management and Accounting | 1 | 5% |
| Social Sciences | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 5 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2013.
All research outputs
#20,193,180
of 22,710,079 outputs
Outputs from Molecular Diagnosis & Therapy
#312
of 376 outputs
Outputs of similar age
#248,719
of 281,582 outputs
Outputs of similar age from Molecular Diagnosis & Therapy
#8
of 8 outputs
Altmetric has tracked 22,710,079 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 376 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,582 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one.